Bleeding Reduction Clinical Trial
Official title:
A Pilot Study Involving the Changes in the Markers of Coagulation During Cardiopulmonary Bypass Surgery Utilizing Acute Normovolemic Hemodilution
This study will help enhance current understanding of the impact of Acute Normovolemic Hemodilution (ANH) administration on transfusion requirements post cardiac surgery, the effect of this procedure on coagulation, and platelet hemostasis, and the amount of chest tube drainage 24 hours post coronary artery bypass graft surgery (CABG) surgery.
Acute Normovolemic Hemodilution (ANH) involves the removal of the patients own blood
immediately at the induction of anesthesia and replacement of this blood intraoperatively
with an equivalent volume of crystalloid or colloid solution in order to dissuade the loss of
red blood cell mass, the mechanism of action is dilution of the blood, hematocrit reduction,
and reduction of the anticoagulant components of the blood associated with bleeding during
cardiopulmonary bypass graft surgery. The collected blood is isolated from the negative
effects of the cardiopulmonary bypass machine.. The collected blood is then stored in
anticoagulant treated blood bags in the cardiovascular operating room and re-infused into the
patient in reverse order of collection at the commencement of surgery, leaving the most cell
rich blood to be re-infused into the patient last. This study will evaluate the effect in
patients with and without ANH utilization on; hemostatic markers, chest tube drainage 24
hours post CABG, and need for allergenic blood transfusion. Positive effects on the
hemostatic markers of anticoagulation and platelets, reduced chest tube drainage at 24 hours
post CABG, and reduced number of transfused red blood cells will indicate a positive
correlation with ANH utilization during isolated on pump CABG surgery.
The benefits of ANH utilization in blood conservation will benefit patients by reducing their
exposure to allogenic blood transfusion with its myriad side effects.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT03070847 -
Low vs. Very Low Dose of Prophylactic Tranexamic Acid for Bleeding Reduction During Rhinoplasty
|
Phase 4 |